Hepatitis C virus and glucose and lipid metabolismVirus de l’hépatite C et métabolisme du glucose et des lipides

https://doi.org/10.1016/S1262-3636(08)74606-8Get rights and content

Abstract

The hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. Its spectrum of severity, however, varies widely, as does its rate of progression towards cirrhosis. This depends on several host-related cofactors, such as age, gender, alcohol consumption, over weight and co-infections. The objective of this review is to discuss two of these cofactors: steatosis and insulin resistance. Although both may occur independently of HCV, a direct role of HCV infection in their pathogenesis has been reported. Whereas the virus-induced steatosis does not seem to have major clinical consequences, the so-called ‘metabolic’ steatosis and underlying insulin resistance may not only modify the clinical and histological course of chronic hepatitis C, but may also influence the response to interferon alpha-based therapy.

Résumé

Le virus de l’hépatite C (VHC) est une importante cause de maladies chroniques du foie dans le monde entier. Sa gravité est pourtant très variable, tout comme son taux de progression vers la cirrhose. Cela dépend de la présence de plusieurs cofacteurs liés à l’hôte, tels que l’âge, le sexe, la consmmation d’alcool, le surpoids et certaines coinfections. Dans cette revue, nous allons discuter de deux de ces facteurs, la stéatose et l’insulinorésistance. Bien que ces deux facteurs puissent être présents indépendammant du VHC, un rôle direct de l’infection par VHC dans leur pathogenèse a été rapporté. La stéatose virale ne paraît pas avoir des conséquences majeures sur le plan clinique. Au contraire, la stéatose métabolique (ainsi que la sous-jacente insulinorésistance) est capable de modifier l’histoire clinique ainsi que la progression histologique de l’hépatite C chronique, et aussi influencer la réponse au traitement par interféron alpha.

Introduction

The hepatitis C virus (HCV) is a major cause of chronic liver disease, affecting an estimated 170 million people worldwide. The spectrum of severity of the liver disease associated with HCV—from minimal liver damage to full-blown hepatitis, both acute and chronic—varies widely as does its rate of progression towards cirrhosis. This rate seems to depend on many host-related cofactors such as age, gender, alcohol consumption, overweight and co-infections [1], [2]. The objective of this review is to discuss two such cofactors-steatosis and insulin resistance. Although both may occur independently of HCV, a direct role of HCV infection is now accepted in their pathogenesis. Steatosis and insulin resistance may not only modify the course of chronic hepatitis C, but may also influence the response to interferon alpha-based therapy.

Section snippets

HCV and steatosis

Liver steatosis is the accumulation of triglycerides in hepatocytes, and is a common finding in any chronic liver disease. Liver steatosis and steatohepatitis, once thought to arise only as a result of alcohol consumption, are now most often seen in association with the metabolic syndrome. The concomitance of increased fatty acid synthesis and the free fatty acid overflow to hepatocytes that accompanies the metabolic syndrome are the major pathogenic mechanisms leading to fatty liver in these

Clinical impact of HCV-induced steatosis

Steatosis has been reported to contribute to disease progression in chronic hepatitis C [2], [3], [9]. Steatosis on the initial biopsy has been associated with a more rapid development of fibrosis [40], [41], [42], [43], [44], [45], higher risk of hepatocellular carcinoma (HCC) [46] and decreased response to antiviral therapy [43]. In view of the discordant data reported in the literature, especially concerning the relative contribution of the different genotypes to liver fibrosis [41], [42],

HCV and insulin resistance

Insulin resistance is defined as a condition in which higherthan-normal insulin concentrations are needed to achieve normal metabolic responses or, alternatively, normal insulin concentrations are unable to achieve normal metabolic responses [51]. Even before we started measuring the level of insulin resistance in chronic hepatitis C patients, most often by measuring the homeostasis assessment score of insulin resistance, known as HOMA score, several reports suggested an association between HCV

HCV interference with insulin signaling

Experimental data suggest a direct interference of HCV with the insulin cascade. This was first shown by a study where liver specimens obtained from 42 non-obese and non-diabetic HCV-infected subjects and 10 non-HCV-infected subjects matched for age and BMI were exposed ex vivo to insulin, and examined for the contents and phosphorylation/activation status of insulin-signaling molecules [72]. Insulin-stimulated IRS-1 tyrosine phosphorylation was decreased twofold in HCV-infected patients

Clinical consequences of insulin resistance in hepatitis C

There are two major clinical consequences of the insulinresistant state associated with hepatitis C, independent of its pathogenesis: the accelerated progression of liver fibrosis; and the reduced response to therapy. We have already mentioned the role of non-virus-induced steatosis as an independent predictor of fibrosis [47]. The mechanisms by which non-viral steatosis can promote liver fibrosis range from oxidative stress to proinflammatory cytokines, insulin resistance and increased

References (99)

  • L. Serfaty et al.

    Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C

    J Hepatol

    (2001)
  • K. Abid et al.

    An in vitro model of hepatitis C virus genotype 3aassociated triglycerides accumulation

    J Hepatol

    (2005)
  • S. Mirandola et al.

    Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis

    Gastroenterology

    (2006)
  • T. Tsutsumi et al.

    Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity

    Hepatology

    (2002)
  • S. Dharancy et al.

    Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection

    Gastroenterology

    (2005)
  • C. Jackel-Cram et al.

    Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein:genotype 3a core has stronger effect than genotype 1b core

    J Hepatol

    (2007)
  • A. Shavinskaya et al.

    The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly

    J Biol Chem

    (2007)
  • J. Westin et al.

    Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

    J Hepatol

    (2002)
  • H. Patton et al.

    The impact of steatosis on disease in chronic hepatitis C patients

    J Hepatol

    (2004)
  • G. Leandro et al.

    Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data

    Gastroenterology

    (2006)
  • S. Zeuzem et al.

    Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3

    J Hepatol

    (2004)
  • J.M. Hui et al.

    Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression

    Gastroenterology

    (2003)
  • M.E.D. Allison et al.

    Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population

    J Hepatol

    (1994)
  • S.H. Mehta et al.

    Hepatitis C virus infection and incident type 2 diabetes

    Hepatology

    (2003)
  • R. Moucari et al.

    Insulin resistance in chronic hepatitis C:association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

    Gastroenterology

    (2008)
  • M. Romero-Gómez et al.

    Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C

    J Hepatol

    (2008)
  • S. Aytug et al.

    Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

    Hepatology

    (2003)
  • Y. Shintani et al.

    Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

    Gastroenterology

    (2004)
  • T. Kawaguchi et al.

    Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3

    Am J Pathol

    (2004)
  • C. Bernsmeier et al.

    Virus induced over-expression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C

    J Hepatol

    (2008)
  • H. Knobler et al.

    Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association

    Am J Gastroenterol

    (2003)
  • H. Lerat et al.

    Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

    Gastroenterology

    (2002)
  • M. Okuda et al.

    Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

    Gastroenterology

    (2002)
  • V. Ratziu et al.

    Fibrogenic impact of high serum glucose in chronic hepatitis C

    J Hepatol

    (2003)
  • I.J. Hickman et al.

    In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis:implications for therapy

    J Hepatol

    (2003)
  • V. Paradis et al.

    High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

    Hepatology

    (2001)
  • N. Akuta et al.

    Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

    J Hepatol

    (2002)
  • M. Romero-Gomez et al.

    Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients

    Gastroenterology

    (2005)
  • H. Poustchi et al.

    Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3

    J Hepatol

    (2008)
  • E. Larrea et al.

    Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C

    Hepatology

    (1996)
  • M. Gadina et al.

    Signaling by type I and II cytokine receptors:ten years after

    Curr Opin Immunol

    (2001)
  • K. Overbeck et al.

    Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

    J Hepatol

    (2008)
  • S.H. Caldwell et al.

    Obesity and hepatocellular carcinoma

    Gastroenterology

    (2004)
  • A. Alberti et al.

    Review article: chronic hepatitis C – Natural history and cofactors

    Aliment Pharmacol Ther

    (2005)
  • T. Asselah et al.

    Steatosis in chronic hepatitis C: why does it really matter?

    Gut

    (2006)
  • S.J. Hwang et al.

    Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

    J Gastroenterol Hepatol

    (2001)
  • S. Mihm et al.

    Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype

    Hepatology

    (1997)
  • T. Poynard et al.

    Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C

    Hepatology

    (2003)
  • F. Negro

    Mechanisms and significance of liver steatosis in hepatitis C virus infection

    World J Gastroenterol

    (2006)
  • Cited by (23)

    • Chronic HCV infection increases cardiac left ventricular mass index in normotensive patients

      2014, Journal of Hepatology
      Citation Excerpt :

      Interestingly, eradication of HCV by antiviral therapy induced a significant improvement in insulin sensitivity reducing the risk of incident T2DM [6,34,35], emphasising the importance of viral infection. In this context, another important open question remains the association of HCV viral load and the severity of IR [36]. Remarkably, our data demonstrate a significant strong relationship between viral load and both IR and LVM, thus confirming the close association among HCV infection, metabolic alterations and subclinical organ damage.

    • Lipid and carbohydrate parameters in children with chronic hepatitis C

      2011, Advances in Medical Sciences
      Citation Excerpt :

      Since the HCV virus was discovered in 1989, a possible association has been noted between chronic hepatitis and abnormalities in lipid and glucose levels, and hepatic steatosis and lipid disturbances have been considered to be characteristics of HCV infection. A correlation between HCV infection and the development of insulin resistance and diabetes has been recently highlighted in studies on the adult population. [4,5,17]. The aim of this study was the evaluation of lipid and carbohydrate parameters in children with CHC.

    • Management of chronic liver disease by general practitioners in Southern Italy: Unmet educational needs

      2011, Digestive and Liver Disease
      Citation Excerpt :

      Therefore, the link between liver steatosis, the metabolic syndrome, and HCV infection matters [34]. Differences amongst HCV genotypes exist; in patients with genotype 3, steatosis directly correlates with viral load; this condition is sustained by an impaired VLDL assembly and secretion and by an up-regulation of the sterol depending protein signalling pathway which regulates de novo lipogenesis and inhibits mitochondrial β-oxidation [35]. By contrast in non-3 genotypes, steatosis is associated with increased BMI and insulin-resistance.

    View all citing articles on Scopus
    View full text